More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$4.61B
EPS
-0.44
P/E ratio
--
Price to sales
13.72
Dividend yield
--
Beta
2.182049
Previous close
$27.87
Today's open
$28
Day's range
$27.62 - $29.18
52 week range
$12 - $32.21
show more
CEO
Chad Robins
Employees
624
Headquarters
Seattle, WA
Exchange
Nasdaq Global Select
Shares outstanding
161876694
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Adaptive Biotechnologies Highlights clonoSEQ's Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies
GlobeNewsWire • 15 hours ago

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UKPresentation on Wednesday, November 18, 2026, at 4:00 p.m.
GlobeNewsWire • Nov 10, 2026

Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?
Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research • Nov 10, 2026

Adaptive Biotechnologies Q3 Earnings Call Highlights
Adaptive Biotechnologies NASDAQ: ADPT reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in both clinical care and drug development.
MarketBeat • Nov 5, 2026

Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2026. “Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies.
GlobeNewsWire • Nov 4, 2026

Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates
Adaptive Biotechnologies (ADPT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.15 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Nov 5, 2026

Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure
Adaptive Biotechnologies benefits from new NCCN guidelines and IMS cure definitions, positioning clonoSEQ as the standard for long-term myeloma MRD monitoring. MRD revenues grew 33% year-over-year to $66.2M, with clinical ASP up 7% and test volumes up 43%, driving adjusted EBITDA margin to 14%. Elimination of the OrbiMed revenue share and a $345M zero-coupon note refinancing provide ADPT with over five years of runway and remove a major growth tax.
Seeking Alpha • Oct 27, 2026

Alger Small Cap Focus Fund Q3 2026 Portfolio Update
Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were among the top detractors from performance. VSE Corporation shares detracted from performance during the quarter despite strong revenue growth, record profitability, and an improved full-year outlook.
Seeking Alpha • Oct 23, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Adaptive Biotechnologies Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.